Beckman Coulter has been one of IDL Biotech’s most successful tumor markers distributors, and has sold the products in the Czech Republic and Slovakia for many years. With Beckman Coulter now taking over the global distribution rights for the company’s tumor markers, we can intensify our focus on rapid testing and automation. At the same time, it gives Beckman Coulter the opportunity to broaden his product portfolio within tumor markers, says Charlotte Berg, CEO of IDL Biotech.
IDL Biotech will continue to produce the tumor markers. The agreement is global, excluding the Chinese market.
Read the press release here
